Ubenimex Clinical Study

Ubenimex Clinical Study 2017-06-15T23:08:57+00:00

About the Phase 2 LIBERTY Study

LIBERTY is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study of ubenimex in patients with PAH, with planned enrollment of 45-60 patients randomized in a 2:1 ratio to receive ubenimex or matching placebo, administered orally for a total of 24 weeks.  Patients who complete treatment through Week 24 are eligible to enroll in an open-label extension study to receive continued treatment.  This open-label extension will allow all patients the option to receive ubenimex for at least 24 additional weeks and provide additional data on safety, tolerability and efficacy, with many patients treated with ubenimex for greater than 24 weeks.  See clinicaltrials.gov: NCT02664558.

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension